Search

Displaying results 171 - 180 of 6079 in total
  1. Drug

    Doxorubicin

    go.drugbank.com/drugs/DB00997
    ApprovedInvestigational

    Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970. Although they both have aglyconic and sugar moieties, doxor...

    Synonyms: MTC-DOX for InjectionProducts: DOXABIN POWDER FOR SOLUTION FOR INJECTION 10MG/VIAL, DOXABIN POWDER FOR SOLUTION FOR INJECTION 50MG/VIAL
  2. Drug

    Fondaparinux

    go.drugbank.com/drugs/DB00569
    ApprovedInvestigational

    The monomeric sequence in heparin and HS is thought to form the high affinity binding site for the natural anti-coagulant factor, antithrombin III (ATIII).

    Products: ARIXTRA 12.5MG/ML SOLUTION FOR INJECTION, ARIXTRA 2.5MG/0.5ML SOLUTION FOR INJECTION
  3. Drug

    Technetium Tc-99m sulfur colloid

    go.drugbank.com/drugs/DB09397
    Approved

    a radiopharmaceutical diagnostic agent used in the evaluation of various conditions including lymph node metastases in breast cancer, detection of shunt patency, imaging of reticuloendothelial cells for

    Products: Kit for the Preparation of Technetium Tc 99m Sulfur Colloid, Kit for the Prepartion of Technetium Tc99m Sulfur Colloid
  4. Drug

    Epoprostenol

    go.drugbank.com/drugs/DB01240
    ApprovedInvestigational

    A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue. The sodium salt has been also used to treat primary pulmonary...

    Products: VELETRI POWDER FOR SOLUTION FOR INFUSION 0.5MG/VIAL, VELETRI POWDER FOR SOLUTION FOR INFUSION 1.5MG/VIAL
  5. Drug

    Pegfilgrastim

    go.drugbank.com/drugs/DB00019
    ApprovedInvestigational

    [A187601] The drug is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with with non-myeloid cancer receiving myelosuppressive anti-cancer … [L9974] NIOPEG (pegfilgrastim), a biosimilar of NEULASTA®, was approved by Health Canada in April 2024 for the prevention of febrile neutropenia in patients with non-myeloid malignancies receiving myelosuppressive

    Products: Pelgraz 6 mg solution for injection in a pre-filled syringe, Pelgraz Solution for Injection in pre-filled syringe 6mg/0.6mL
  6. Drug

    Enfortumab vedotin

    go.drugbank.com/drugs/DB13007
    ApprovedInvestigational

    The clinical development of enfortumab vedotin was the result of a collaboration between Astellas Pharma and Seattle Genetics [A188868] and it was first approved for use in the United States in December

    Products: Padcev 30mg Powder for Concentrate for Solution for Infusion, Padcev 20mg Powder for Concentrate for Solution for Infusion
  7. Drug

    Exenatide

    go.drugbank.com/drugs/DB01276
    ApprovedInvestigational

    Exenatide is a glucagon-like peptide-1 (GLP-1) analog . It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control . Exenatide was given FDA appro...

    Products: BYDUREON 2 mg powder and solvent for prolonged-release suspension for injection, BYDUREON POWDER AND SOLVENT FOR PROLONGED-RELEASE SUSPENSION FOR INJECTION IN PRE-FILLED PEN 2MG
  8. Drug

    Streptomycin

    go.drugbank.com/drugs/DB01082
    ApprovedInvestigationalVet approved

    [A233325,A233390] Selman Waksman and eventually Albert Schatz were recognized with the Nobel Prize in Medicine for their discovery of streptomycin and its antibacterial activity.

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseProducts: Streptomycin for Injection USP, STREPTOMYCIN SULFATE FOR INJECTION 1 g/vial
  9. Drug

    Paliperidone

    go.drugbank.com/drugs/DB01267
    ApprovedInvestigational

    Paliperidone was approved by the FDA for treatment of schizophrenia on December 20, 2006.

    Products: INVEGA Sustenna Prolonged Release Suspension for IM Injection 25mg/0.25 ml, INVEGA Sustenna Prolonged Release Suspension for IM Injection 50mg/0.5 ml
  10. Drug

    Alemtuzumab

    go.drugbank.com/drugs/DB00087
    ApprovedInvestigational

    The dose of alemtuzumab used for B-CLL is much higher than that for MS, and also at more frequent dosing.[L43397, L30335] … [L43397] It is marketed as LEMTRADA for multiple sclerosis (MS) treatment and CAMPTAH for B-cell chronic lymphocytic leukemia (B-CLL).

    Products: LEMTRADA Concentrate for Solution for Infusion 12 mg, LEMTRADA CONCENTRATE FOR SOLUTION FOR INFUSION 12 MG/ 1.2 ML